No hay productos en el carro de la compra
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Casa > Licensing > BEX202202

PD-1×TIGIT BsAb for Advanced solid tumor

BLA Filing
  • Project profile
    Project name: PD-1×TIGIT BsAb for Advanced solid tumor
    Indications: Advanced solid tumor
    Research phase: Preclinical
    Cooperation demands: License-out or co-development
  • Highlights

    1. Novel strategy for anti-PD-1/PD-L1 treatment resistance

    Clear MOA

    Banta, Karl L et al. “Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses.” Immunity vol. 55,3 (2022): 512-526.

    (1) Despite the great clinical success of immune checkpoint inhibitors, approximately 70% of patients still exhibit ineffective and adaptive resistance in PD-1/PD-L1 blockade anti-tumor therapy.

    (2) TIGIT is an inhibitory receptor, mainly expressed on NK cells and activated T cells and Treg cells. Dual blockade retains the pharmacodynamic activity of PD-1 inhibitors and inhibits the signal of TIGIT simultaneously, which synergistically enhances the efficacy. PD-1×TIGIT BsAb can be a strategy to overcome PD-1/PD-L1 blockade anti-tumor therapy resistance.

    2. Asset binds to PD-1 and TIGIT simultaneously.

    Asset binds to PD-1 and TIGIT simultaneously

    The asset is able to block both PD-1/PD-L1 pathway and TIGIT/CD155 pathway in vitro.

    3. Excellent anti-tumor efficacy.

    Excellent anti-tumor efficacy

    (1) The asset shows enhanced SEB-induced-INF-γ secretion compared with Keytruda (anti-PD-1 mAb) and Tiragolumab (anti-TIGIT mAb) combination therapy, which remains more T cell activation.

    (2) The asset showed superior antitumor activity compared to the combination of Keytruda and Tiragolumab in vivo.

    4. Good safety in preclinical study.

    Cynomolgus monkeys were administered 3 weekly doses of 25 or 50 mg/kg of asset.

    ✓ All animals were survived.
    ✓ No toxicologically significant abnormalities were observed.
    ✓ NOAEL dose: 50 mg/kg.

  • Project Introduction

    1. Asset type: PD-1×TIGIT BsAb

    2. Indication: Advanced solid tumor

    3. Modality:BsAb

    4. Research phase: Preclinical

    5. Cooperation demands: License-out or co-development

    6. Research progress:

    1. Preclinical stage
    2. Anti-tumor efficacy in preclinical study
    3. Good safety

Comments (0)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Correo electrónico
+1 888-377-6111
Lichtstrasse 35,4056 Basel, Switzerland

Dejar un mensaje